Q-omics provides the consensus-scored TSPAN9 profile across patient tissues and cancer cell-line models. TSPAN9 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TSPAN9 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, TSPAN9 protein abundance shows 26,634 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight MESO, HNSC, and GBM as cancer lineages where TSPAN9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSPAN9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSPAN9 survival associations across molecular data types. TSPAN9 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSPAN9 RNA expression–survival associations across cancer types. High TSPAN9 expression shows unfavorable associations in MESO, OV, BLCA, LGG and SKCM, but favorable associations in HNSC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TSPAN9 RNA expression.
This table summarizes TSPAN9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7, while mass-spec protein shows differences in 9. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSPAN9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSPAN9 shows lower tumor expression in LUAD, UCEC and KIRP and higher tumor expression in HNSC, COAD and KIRC. The HNSC box plot shows higher TSPAN9 RNA expression in tumor versus normal tissue (log2 FC = +1.313, t-test p < 0.001).
This table shows molecular features associated with TSPAN9 in patient tissues and cancer cell lines. In patient samples, TSPAN9 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, TSPAN9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and UPPER_AERODIGESTIVE_TRACT.
